Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
3,424
archived clinical trials in
Cognitive Studies

Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Delray Beach, FL
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Delray Beach, FL
Click here to add this to my saved trials
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Lady Lake, FL
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Lady Lake, FL
Click here to add this to my saved trials
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Merritt Island, FL
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Merritt Island, FL
Click here to add this to my saved trials
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Elk Grove, IL
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Elk Grove, IL
Click here to add this to my saved trials
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Farmington Hills, MI
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/31/1969
mi
from
North Ryde,
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/31/1969
mi
from
North Ryde,
Click here to add this to my saved trials
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Petersburg, FL
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Petersburg, FL
Click here to add this to my saved trials
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Biomarker Qualification for Risk of Mild Cognitive Impairment (MCI) Due to Alzheimer's Disease (AD) and Safety and Efficacy Evaluation of Pioglitazone in Delaying Its Onset
A Double Blind, Randomized, Placebo Controlled, Parallel Group Study to Simultaneously Qualify a Biomarker Algorithm for Prognosis of Risk of Developing Mild Cognitive Impairment Due to Alzheimer's Disease (MCI Due to AD) and to Test the Safety and Efficacy of Pioglitazone (AD-4833 SR 0.8 mg QD) to Delay the Onset of MCI Due to AD in Cognitively Normal Subjects
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease
Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease
Novel Retinal Imaging Biomarkers in Early Alzheimer's Disease
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Status: Enrolling
Updated:  12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Olfactory Deficits and Donepezil Treatment in Cognitively Impaired Elderly
Status: Enrolling
Updated: 12/31/1969
New York State Psychiatric Institute
mi
from
New York, NY
Click here to add this to my saved trials
Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)
Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)
Status: Enrolling
Updated:  12/31/1969
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)
Complementary Neurosteroid Intervention in Gulf War Illnesses (GWVI)
Status: Enrolling
Updated: 12/31/1969
Durham VA Medical Center, Durham, NC
mi
from
Durham, NC
Click here to add this to my saved trials
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Status: Enrolling
Updated:  12/31/1969
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Status: Enrolling
Updated: 12/31/1969
Atlanta VA Medical and Rehab Center, Decatur, GA
mi
from
Decatur, GA
Click here to add this to my saved trials
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Status: Enrolling
Updated:  12/31/1969
VA Ann Arbor Healthcare System, Ann Arbor, MI
mi
from
Ann Arbor, MI
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Enhancing Spatial Navigation Using Non-Invasive Brain Stimulation
Status: Enrolling
Updated: 12/31/1969
VA Ann Arbor Healthcare System, Ann Arbor, MI
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women
Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women
Status: Enrolling
Updated:  12/31/1969
University of Pennsylvania, Penn Center for Womens Behavioral Wellness
mi
from
Philadelphia, PA
LDX and Functional Magnetic Resonance Imaging (fMRI in Menopausal Women
Utilizing fMRI to Determine the Effects of Vyvanse® on Memory, Attention, and Brain Activity in Menopausal Women
Status: Enrolling
Updated: 12/31/1969
University of Pennsylvania, Penn Center for Womens Behavioral Wellness
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment
Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment
Status: Enrolling
Updated:  12/31/1969
UCLA Semel Institute
mi
from
Los Angeles, CA
Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment
Memory Training Versus Yogic Meditation Training in Older Adults With Mild Cognitive Impairment
Status: Enrolling
Updated: 12/31/1969
UCLA Semel Institute
mi
from
Los Angeles, CA
Click here to add this to my saved trials
CAndesartan vs LIsinopril Effects on the BRain
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)
Status: Enrolling
Updated:  12/31/1969
Emory Univeristy
mi
from
Atlanta, GA
CAndesartan vs LIsinopril Effects on the BRain
CAndesartan vs LIsinopril Effects on the BRain and Endothelial Function in eXecutive MCI (CALIBREX)
Status: Enrolling
Updated: 12/31/1969
Emory Univeristy
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pivotal Response Treatment for Individuals With Intellectual Disabilities
Pivotal Response Treatment for Individuals With Intellectual Disabilities
Status: Enrolling
Updated:  12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Pivotal Response Treatment for Individuals With Intellectual Disabilities
Pivotal Response Treatment for Individuals With Intellectual Disabilities
Status: Enrolling
Updated: 12/31/1969
Stanford University School of Medicine
mi
from
Stanford, CA
Click here to add this to my saved trials
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
Status: Enrolling
Updated:  12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
Markers of Alzheimers Disease and Cognitive Outcomes After Perioperative Care
Status: Enrolling
Updated: 12/31/1969
Duke Univ Med Ctr
mi
from
Durham, NC
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Banner Health Research Institute
mi
from
Phoenix, AZ
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Banner Health Research Institute
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Banner Sun Health Research Institute
mi
from
Sun City, AZ
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Institute for Memory Impairment & Neurological Disorders
mi
from
Irvine, CA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Institute for Memory Impairment & Neurological Disorders
mi
from
Irvine, CA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
The University of California, San Diego
mi
from
La Jolla, CA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of Southern California School of Medicine
mi
from
Los Angeles, CA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of Southern California School of Medicine
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of California at Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Univ of California Irvine College of Medicine
mi
from
Orange, CA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Univ of California Irvine College of Medicine
mi
from
Orange, CA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of California at San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of California, Davis - Health Systems
mi
from
Walnut Creek, CA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of California, Davis - Health Systems
mi
from
Walnut Creek, CA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Yale University School of Medicine
mi
from
New Haven, CT
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Jacksonville
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Wien Center for Clinical Research
mi
from
Miami Beach, FL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Wien Center for Clinical Research
mi
from
Miami Beach, FL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Compass Research - Orlando
mi
from
Orlando, FL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Compass Research - Orlando
mi
from
Orlando, FL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of South Florida
mi
from
Tampa, FL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of South Florida
mi
from
Tampa, FL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Compass Research -The Villages
mi
from
The Villages, FL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Compass Research -The Villages
mi
from
The Villages, FL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Premiere Research Institute at Palm Beach Neurology
mi
from
West Palm Beach, FL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Premiere Research Institute at Palm Beach Neurology
mi
from
West Palm Beach, FL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Emory University
mi
from
Atlanta, GA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Emory University
mi
from
Atlanta, GA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Northwestern University
mi
from
Chicago, IL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Northwestern University
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Rush Alzheimer's Disease Center
mi
from
Chicago, IL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Rush Alzheimer's Disease Center
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Great Lakes Clinical Trials
mi
from
Chicago, IL
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Great Lakes Clinical Trials
mi
from
Chicago, IL
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Indiana University School of Medicine
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of Iowa
mi
from
Iowa City, IA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of Iowa
mi
from
Iowa City, IA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of Kansas Hospital
mi
from
Fairway, KA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of Kansas Hospital
mi
from
Fairway, KA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of Kentucky
mi
from
Lexington, KY
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of Kentucky
mi
from
Lexington, KY
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Pennington Biomedical Research Center
mi
from
Baton Rouge, LA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Johns Hopkins University School of Medicine
mi
from
Baltimore, MD
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Brigham and Women's Hosp
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Boston University Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
The Mayo Clinic
mi
from
Rochester, MN
Click here to add this to my saved trials
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated:  12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Clinical Trial of Solanezumab for Older Individuals Who May be at Risk for Memory Loss
Anti-Amyloid Treatment in Asymptomatic Alzheimer's Disease (A4 Study)
Status: Enrolling
Updated: 12/31/1969
Univ of Nebraska Med Ctr
mi
from
Omaha, NE
Click here to add this to my saved trials